Cantai Therapeutics, a Waltham, MA-based company that develops drugs to treat autoimmune and inflammatory disorders, raised a seed funding round of undisclosed amount.
The round was led by Agent Capital and 82VS (the affiliated venture studio of Alloy Therapeutics) with additional participation from Tellus BioVentures. In conjunction with the funding, Geeta Vemuri, Ph.D., M.B.A., Founder and Managing Partner of Agent Capital, will be the Board Chair. Errik Anderson, M.B.A., General Partner at 82VS and Founder and Chief Executive Officer at Alloy, will join the Board of Directors.
The company intends to use the funds to develop its drug candidates.
Cantai Therapeutics is advancing drug candadates to treat autoimmune and inflammatory disorders by developing cytokine-targeting bispecific antibodies. Agent conceived the idea for Cantai’s products and partnered with 82VS to further develop the concept. As part of the financing, Alloy will perform services to advance Cantai programs using its broad suite of human antibody discovery technologies, including the ATX-CLC (Common Light Chain) mouse platform for the discovery of bispecific antibody therapeutics.